Their recommended first choice for imaging patients with SDHx mutations (regardless of tumour location) is [68Ga]SSA (gallium-68 labelled somatostatin analogue), with [18F]FDG (fluorine-18 labelled fluorodeoxyglucose) and [18F]FDOPA (fluorine-18 labelled fluorodihydroxyphenylalanine) as second-choice options, consistent with findings that SDH-deficient tumours have higher expression of somatostatin receptors compared to SDH-sufficient tumours (Elston et al. 2015). This evidence concerns the gene SDHB and neoplasm.